Yunyu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunyu Chen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Liona C. Poon
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
5 shared publications - Jing Lin
Department of Obstetrics and Gynaecology, Prince of Wales Hospital The Chinese University of Hong Kong Shatin Hong Kong SAR China
3 shared publications - Alex Pui-Wai Lee
The Chinese University of Hong Kong
2 shared publications - Fangzi Liu
Department of Obstetrics and Gynaecology, Prince of Wales Hospital The Chinese University of Hong Kong Hong Kong SAR China
2 shared publications - Qinjian Zhang
Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital Fujian Medical University Teaching Hospital Fujian China
2 shared publications Aditya Kusuma
Harapan Kita National Women and Children Hospital Jakarta Indonesia
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (5) , 636-646
Regional growth patterns of fetal corpus callosum at 18–32 weeks' gestation assessed by three‐dimensional transvaginal neurosonography
Objectives: To evaluate the normal development of the fetal corpus callosum (CC) between 18 and 32 weeks' gestation using three‐dimensional (3D) transvaginal neurosonography and to assess the effect of volume contrast imaging (VCI) on the measurement of fetal CC biometry. Methods: This study included two cohorts of women with a singleton pregnancy: a prospective cohort attending the research clinic at Prince of Wales Hospital in Hong Kong SAR, China, between April 2019 and February 2025, at which 3D fetal brain volumes were acquired prospectively, and a retrospective cohort attending CRIFM Prenatal Medical Clinic in Osaka, Japan, between December 2018 and March 2025, from which archived 3D fetal brain volume datasets were retrieved. In both cohorts, 3D fetal brain volume data of the CC were acquired using transvaginal neurosonography between 18 and 32 weeks' gestation using the same acquisition protocol. Inclusion criteria were appropriately grown fetuses at 18 + 0 to 32 + 6 weeks' gestation, without suspected structural or chromosomal defects. In the midsagittal plane, using 3D volume multiplanar imaging, the CC length and total area were obtained and regional thickness at the genu, body and splenium were measured following a modified Garel's method. Additionally, the areas of five vertical CC segments defined by arithmetic fractions of the CC length following Witelson's classification (anterior one‐third, anterior midbody, posterior midbody, isthmus and splenium) were obtained. All fetal biometric measurements were performed using non‐VCI and VCI modes. Measurements obtained using non‐VCI and VCI modes were compared using the paired t ‐test. Generalized Additive Models for Location, Scale and Shape (GAMLSS) were used to explore the relationship between all biometric measurements of the fetal CC and gestational age. The final models were used to derive percentiles and construct reference curves. Intra‐ and interobserver variability were assessed using 30 randomly selected cases. Results: A total of 956 fetuses at 18–32 weeks' gestation were included. Gestational age‐specific trajectories of fetal CC biometry were established, demonstrating distinct, non‐linear growth patterns in CC length, total area, genu, body and splenium thicknesses and the areas of five individual CC subdivisions from 18 to 32 weeks. Overall, the genu and body thicknesses increased sharply from 18 weeks to 23 weeks. Thereafter, genu thickness continued to increase gradually until 32 weeks, whereas body thickness plateaued before showing renewed growth at 31–32 weeks. The percentile curve for fetal CC total area demonstrated a steady increase from 18 to 32 weeks. Among the five subdivisions of the CC, the splenium demonstrated the most pronounced absolute area growth, reaching a median of approximately 0.40 cm 2 by 32 weeks, with markedly greater expansion than the midbody regions throughout the second to early third trimesters. Fetal CC biometric measurements were comparable between non‐VCI and VCI measurements. Overall, the biometric measurements demonstrated high reproducibility, with most showing good‐to‐excellent intra‐ and interobserver reliability, except for moderate interobserver reliability for genu and body thicknesses. Conclusions: We have characterized region‐specific non‐linear growth patterns in fetal CC development from 18 to 32 weeks, with posterior‐predominant area expansion most pronounced in the splenium. The clinical significance of regional CC measurements remains uncertain, and the presented trajectories should be regarded as descriptions of normal developmental patterns rather than as reference charts for isolated clinical decision‐making. Longitudinal studies incorporating postnatal neurodevelopmental assessment will be required to determine their prognostic value. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 21 October 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (5) , 636-646
Open AccessRegional growth patterns of fetal corpus callosum at 18–32 weeks' gestation assessed by three‐dimensional transvaginal neurosonography
Objectives: To evaluate the normal development of the fetal corpus callosum (CC) between 18 and 32 weeks' gestation using three‐dimensional (3D) transvaginal neurosonography and to assess the effect of volume contrast imaging (VCI) on the measurement of fetal CC biometry. Methods: This study included two cohorts of women with a singleton pregnancy: a prospective cohort attending the research clinic at Prince of Wales Hospital in Hong Kong SAR, China, between April 2019 and February 2025, at which 3D fetal brain volumes were acquired prospectively, and a retrospective cohort attending CRIFM Prenatal Medical Clinic in Osaka, Japan, between December 2018 and March 2025, from which archived 3D fetal brain volume datasets were retrieved. In both cohorts, 3D fetal brain volume data of the CC were acquired using transvaginal neurosonography between 18 and 32 weeks' gestation using the same acquisition protocol. Inclusion criteria were appropriately grown fetuses at 18 + 0 to 32 + 6 weeks' gestation, without suspected structural or chromosomal defects. In the midsagittal plane, using 3D volume multiplanar imaging, the CC length and total area were obtained and regional thickness at the genu, body and splenium were measured following a modified Garel's method. Additionally, the areas of five vertical CC segments defined by arithmetic fractions of the CC length following Witelson's classification (anterior one‐third, anterior midbody, posterior midbody, isthmus and splenium) were obtained. All fetal biometric measurements were performed using non‐VCI and VCI modes. Measurements obtained using non‐VCI and VCI modes were compared using the paired t ‐test. Generalized Additive Models for Location, Scale and Shape (GAMLSS) were used to explore the relationship between all biometric measurements of the fetal CC and gestational age. The final models were used to derive percentiles and construct reference curves. Intra‐ and interobserver variability were assessed using 30 randomly selected cases. Results: A total of 956 fetuses at 18–32 weeks' gestation were included. Gestational age‐specific trajectories of fetal CC biometry were established, demonstrating distinct, non‐linear growth patterns in CC length, total area, genu, body and splenium thicknesses and the areas of five individual CC subdivisions from 18 to 32 weeks. Overall, the genu and body thicknesses increased sharply from 18 weeks to 23 weeks. Thereafter, genu thickness continued to increase gradually until 32 weeks, whereas body thickness plateaued before showing renewed growth at 31–32 weeks. The percentile curve for fetal CC total area demonstrated a steady increase from 18 to 32 weeks. Among the five subdivisions of the CC, the splenium demonstrated the most pronounced absolute area growth, reaching a median of approximately 0.40 cm 2 by 32 weeks, with markedly greater expansion than the midbody regions throughout the second to early third trimesters. Fetal CC biometric measurements were comparable between non‐VCI and VCI measurements. Overall, the biometric measurements demonstrated high reproducibility, with most showing good‐to‐excellent intra‐ and interobserver reliability, except for moderate interobserver reliability for genu and body thicknesses. Conclusions: We have characterized region‐specific non‐linear growth patterns in fetal CC development from 18 to 32 weeks, with posterior‐predominant area expansion most pronounced in the splenium. The clinical significance of regional CC measurements remains uncertain, and the presented trajectories should be regarded as descriptions of normal developmental patterns rather than as reference charts for isolated clinical decision‐making. Longitudinal studies incorporating postnatal neurodevelopmental assessment will be required to determine their prognostic value. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 28 September 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (4) , 527-539
Postpartum anthropometric and cardiovascular profile following hypertensive disorders of pregnancy: 12‐month follow‐up
Objectives: To compare anthropometric and cardiovascular parameters at 6–12 weeks postpartum among women classified at first‐trimester screening as high risk for pre‐eclampsia (PE) who subsequently developed hypertensive disorders of pregnancy (HDP), those classified as high risk who did not develop HDP and those classified as low risk for PE, and, among high‐risk women, to evaluate the trajectory of these parameters from 6–12 weeks to 12 months postpartum according to the subsequent development of HDP. Methods: This was a prospective postpartum longitudinal study conducted at the Prince of Wales Hospital, Hong Kong Special Administrative Region, in which women underwent postpartum assessment between October 2022 and January 2025. Eligible participants were Chinese women in the postpartum period following a singleton pregnancy who had undergone first‐trimester PE screening at 11 + 0 to 13 + 6 weeks' gestation. Women were classified into three groups based on their first‐trimester screening result and subsequent pregnancy outcome: (1) women at high risk (≥ 1:100) for PE who subsequently developed HDP; (2) women at high risk for PE who did not develop HDP; and (3) low‐risk controls with a normotensive pregnancy. Participants were enrolled between 6 and 12 weeks postpartum for anthropometric and cardiovascular assessments, and these findings were compared among the groups. Subsequently, women at high risk for PE were examined longitudinally at 6 months and 12 months postpartum to assess changes in anthropometric and cardiovascular parameters. High‐risk women received lifestyle counseling at each visit. Linear mixed‐effects analysis was performed to compare the longitudinal changes in anthropometric and cardiovascular parameters over the postpartum period. Results: Overall, 201 women were included in the study, of whom 130 were at high risk for PE and did not develop HDP, 41 were at high risk for PE and developed HDP and 30 were low‐risk controls. At 6–12 weeks postpartum, high‐risk women with HDP exhibited a significantly higher mean arterial pressure, left ventricular (LV) mass index (MI), systemic vascular resistance, myocardial performance index and more impaired global longitudinal strain (GLS), along with lower mitral annular plane systolic excursion, compared with the low‐risk and high‐risk‐without‐HDP groups. Similar findings mostly persisted over the 12‐month postpartum period, even after adjusting for risk factors (all P < 0.05). From 6 to 12 weeks to 12 months postpartum, the high‐risk‐without‐HDP group showed a statistically significant declining trend in weight, waist circumference and waist‐to‐hip ratio, along with reduced weight gain from the first trimester to 12 months postpartum, whereas the high‐risk‐with‐HDP group showed no significant change during the same period. The high‐risk‐without‐HDP group exhibited a decreasing trend in LV‐MI and increasing trends in LV ejection fraction, GLS, left atrial emptying fraction and left atrial expansion index from 6–12 weeks to 6 months postpartum. Conversely, in the high‐risk‐with‐HDP group, these improvements only became apparent at 12 months postpartum (all P < 0.05). Conclusions: Women identified as being at high risk for PE at first‐trimester screening, particularly those who develop HDP, exhibit consistently suboptimal anthropometric and cardiovascular trajectories during the first year postpartum. The observed association between maternal risk factors and an unfavorable cardiovascular profile underscores the need to extend anthropometric and cardiovascular screening and implement personalized interventions beyond the standard 6–12‐week postpartum visit in women with HDP. However, the feasibility and practicality of postpartum cardiovascular surveillance are limited by disparities in access to echocardiography, resource allocation for prolonged follow‐up and challenges in improving patient engagement in postpartum care. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 28 September 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (4) , 527-539
Open AccessPostpartum anthropometric and cardiovascular profile following hypertensive disorders of pregnancy: 12‐month follow‐up
Objectives: To compare anthropometric and cardiovascular parameters at 6–12 weeks postpartum among women classified at first‐trimester screening as high risk for pre‐eclampsia (PE) who subsequently developed hypertensive disorders of pregnancy (HDP), those classified as high risk who did not develop HDP and those classified as low risk for PE, and, among high‐risk women, to evaluate the trajectory of these parameters from 6–12 weeks to 12 months postpartum according to the subsequent development of HDP. Methods: This was a prospective postpartum longitudinal study conducted at the Prince of Wales Hospital, Hong Kong Special Administrative Region, in which women underwent postpartum assessment between October 2022 and January 2025. Eligible participants were Chinese women in the postpartum period following a singleton pregnancy who had undergone first‐trimester PE screening at 11 + 0 to 13 + 6 weeks' gestation. Women were classified into three groups based on their first‐trimester screening result and subsequent pregnancy outcome: (1) women at high risk (≥ 1:100) for PE who subsequently developed HDP; (2) women at high risk for PE who did not develop HDP; and (3) low‐risk controls with a normotensive pregnancy. Participants were enrolled between 6 and 12 weeks postpartum for anthropometric and cardiovascular assessments, and these findings were compared among the groups. Subsequently, women at high risk for PE were examined longitudinally at 6 months and 12 months postpartum to assess changes in anthropometric and cardiovascular parameters. High‐risk women received lifestyle counseling at each visit. Linear mixed‐effects analysis was performed to compare the longitudinal changes in anthropometric and cardiovascular parameters over the postpartum period. Results: Overall, 201 women were included in the study, of whom 130 were at high risk for PE and did not develop HDP, 41 were at high risk for PE and developed HDP and 30 were low‐risk controls. At 6–12 weeks postpartum, high‐risk women with HDP exhibited a significantly higher mean arterial pressure, left ventricular (LV) mass index (MI), systemic vascular resistance, myocardial performance index and more impaired global longitudinal strain (GLS), along with lower mitral annular plane systolic excursion, compared with the low‐risk and high‐risk‐without‐HDP groups. Similar findings mostly persisted over the 12‐month postpartum period, even after adjusting for risk factors (all P < 0.05). From 6 to 12 weeks to 12 months postpartum, the high‐risk‐without‐HDP group showed a statistically significant declining trend in weight, waist circumference and waist‐to‐hip ratio, along with reduced weight gain from the first trimester to 12 months postpartum, whereas the high‐risk‐with‐HDP group showed no significant change during the same period. The high‐risk‐without‐HDP group exhibited a decreasing trend in LV‐MI and increasing trends in LV ejection fraction, GLS, left atrial emptying fraction and left atrial expansion index from 6–12 weeks to 6 months postpartum. Conversely, in the high‐risk‐with‐HDP group, these improvements only became apparent at 12 months postpartum (all P < 0.05). Conclusions: Women identified as being at high risk for PE at first‐trimester screening, particularly those who develop HDP, exhibit consistently suboptimal anthropometric and cardiovascular trajectories during the first year postpartum. The observed association between maternal risk factors and an unfavorable cardiovascular profile underscores the need to extend anthropometric and cardiovascular screening and implement personalized interventions beyond the standard 6–12‐week postpartum visit in women with HDP. However, the feasibility and practicality of postpartum cardiovascular surveillance are limited by disparities in access to echocardiography, resource allocation for prolonged follow‐up and challenges in improving patient engagement in postpartum care. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 2 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2074
Preeclampsia Screening
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. This significant burden necessitates effective early identification of pregnancies at high-risk for preeclampsia. Accurate prediction is essential in order to develop and optimize preventive strategies. The evolution of preeclampsia screening has progressed from a traditional checklist-based approach to individualized, multivariable models. The first-trimester triple test, which was developed by the Fetal Medicine Foundation (FMF), represents this advancement. It utilizes Bayes’ theorem to calculate patient-specific risks by integrating maternal factors, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. This model, called “first trimester FMF triple test”, has undergone successful internal and external validation for the prediction of preterm preeclampsia. To ensure the reliability of biomarker measurements and achieve an optimal screening performance, it is essential to implement standardized measurement protocols and rigorous quality control processes in biomarker testing. The triple test could also be utilized in the 2nd and 3rd trimester, and the addition of biomarkers such as soluble fms-like tyrosine kinase-1 further improves risk stratification assessment and continued surveillance of high-risk pregnancies.
- 2 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2074
Open AccessPreeclampsia Screening
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. This significant burden necessitates effective early identification of pregnancies at high-risk for preeclampsia. Accurate prediction is essential in order to develop and optimize preventive strategies. The evolution of preeclampsia screening has progressed from a traditional checklist-based approach to individualized, multivariable models. The first-trimester triple test, which was developed by the Fetal Medicine Foundation (FMF), represents this advancement. It utilizes Bayes’ theorem to calculate patient-specific risks by integrating maternal factors, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. This model, called “first trimester FMF triple test”, has undergone successful internal and external validation for the prediction of preterm preeclampsia. To ensure the reliability of biomarker measurements and achieve an optimal screening performance, it is essential to implement standardized measurement protocols and rigorous quality control processes in biomarker testing. The triple test could also be utilized in the 2nd and 3rd trimester, and the addition of biomarkers such as soluble fms-like tyrosine kinase-1 further improves risk stratification assessment and continued surveillance of high-risk pregnancies.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics
BACKGROUND: The effect of parity and previous preeclampsia on the longitudinal maternal hemodynamics during pregnancy has not been studied. METHODS: This was a prospective longitudinal study of maternal hemodynamic profile, assessed by transthoracic echocardiography, for women at 12 +0 to 15 +6 , 20 +0 to 24 +6 , and 30 +0 to 37 +6 weeks of gestation. The study populations were divided into 3 groups: nulliparous women and parous women with and without previous preeclampsia. A linear mixed-effects analysis was performed to compare the longitudinal changes in hemodynamics across gestation among the study groups, controlling for maternal characteristics and medical history in the index pregnancy. RESULTS: Our study involved 760 nulliparous women, 318 parous women without previous preeclampsia, and 59 parous women with previous preeclampsia. The parous with previous preeclampsia group had the highest median mean arterial pressure and systemic vascular resistance compared with the other 2 groups throughout gestation (all P +6 and 30 +0 to 37 +6 weeks. Parous women without previous preeclampsia demonstrated a higher estimated marginal mean of cardiac output and a lower estimated marginal mean of systemic vascular resistance compared with nulliparous women throughout gestation (all P <0.05). CONCLUSIONS: The study has revealed that parous women without previous preeclampsia show optimal cardiovascular responses. In contrast, those with a history of preeclampsia exhibit suboptimal cardiovascular adaptation, and the cardiovascular changes observed from the second trimester in the index pregnancy are attributed to maternal characteristics and the development of preeclampsia.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics
BACKGROUND: The effect of parity and previous preeclampsia on the longitudinal maternal hemodynamics during pregnancy has not been studied. METHODS: This was a prospective longitudinal study of maternal hemodynamic profile, assessed by transthoracic echocardiography, for women at 12 +0 to 15 +6 , 20 +0 to 24 +6 , and 30 +0 to 37 +6 weeks of gestation. The study populations were divided into 3 groups: nulliparous women and parous women with and without previous preeclampsia. A linear mixed-effects analysis was performed to compare the longitudinal changes in hemodynamics across gestation among the study groups, controlling for maternal characteristics and medical history in the index pregnancy. RESULTS: Our study involved 760 nulliparous women, 318 parous women without previous preeclampsia, and 59 parous women with previous preeclampsia. The parous with previous preeclampsia group had the highest median mean arterial pressure and systemic vascular resistance compared with the other 2 groups throughout gestation (all P +6 and 30 +0 to 37 +6 weeks. Parous women without previous preeclampsia demonstrated a higher estimated marginal mean of cardiac output and a lower estimated marginal mean of systemic vascular resistance compared with nulliparous women throughout gestation (all P <0.05). CONCLUSIONS: The study has revealed that parous women without previous preeclampsia show optimal cardiovascular responses. In contrast, those with a history of preeclampsia exhibit suboptimal cardiovascular adaptation, and the cardiovascular changes observed from the second trimester in the index pregnancy are attributed to maternal characteristics and the development of preeclampsia.
- Open Access
- 14 May 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (10) , 1460-1468
Impact of Aspirin on Timing of Birth in Pregnancies With Clinical Manifestations of Placental Dysfunction: Evidence From a Multicentre Randomised Clinical Trial
Objective: To examine whether aspirin delays gestational age at delivery (GAD) in pregnancies with placental dysfunction (PD) phenotypes (preeclampsia [PE], small‐for‐gestational‐age [SGA], placental abruption and/or stillbirth).Design: A secondary analysis of a multicentre stepped‐wedge cluster randomised trial.Setting: 18 maternity/diagnostic units in Asia.Population: Singleton pregnancies examined at 11–13+6 weeks.Methods: A model in which the effect of aspirin is to delay the GAD in pregnancies with PD was developed.Main Outcome Measures: GAD in pregnancies with PD.Results: Aspirin administration was associated with a significant reduction in PD < 32 weeks (adjusted relative risk 0.543, 95% CI: 0.330–0.864), with a trend for an increase of PD ≥ 32 weeks (test for trend, p‐value = 0.0018). Similar findings were observed individually for PE, SGA and/or placental abruption. At 24 weeks, the aspirin‐induced prolongation of pregnancies with PD was 2.85 weeks (95% CI: 0.44–5.40), and this effect was decreased by −0.19 weeks (95% CI: −0.33 to −0.05) for each week of gestation; therefore, at 28 and 32 weeks' gestation, the aspirin‐induced prolongation was 2.09 and 1.33 weeks, respectively.Conclusions: In this secondary analysis of a cluster randomised trial, women at high risk of PE who are destined to develop a clinical spectrum of PD may benefit from longer pregnancy duration through aspirin administration in early pregnancy. Aspirin may delay the GAD due to PD, particularly benefiting those deliveries that would occur at earlier gestations without aspirin administration.
- 14 May 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (10) , 1460-1468
Open AccessImpact of Aspirin on Timing of Birth in Pregnancies With Clinical Manifestations of Placental Dysfunction: Evidence From a Multicentre Randomised Clinical Trial
Objective: To examine whether aspirin delays gestational age at delivery (GAD) in pregnancies with placental dysfunction (PD) phenotypes (preeclampsia [PE], small‐for‐gestational‐age [SGA], placental abruption and/or stillbirth).Design: A secondary analysis of a multicentre stepped‐wedge cluster randomised trial.Setting: 18 maternity/diagnostic units in Asia.Population: Singleton pregnancies examined at 11–13+6 weeks.Methods: A model in which the effect of aspirin is to delay the GAD in pregnancies with PD was developed.Main Outcome Measures: GAD in pregnancies with PD.Results: Aspirin administration was associated with a significant reduction in PD < 32 weeks (adjusted relative risk 0.543, 95% CI: 0.330–0.864), with a trend for an increase of PD ≥ 32 weeks (test for trend, p‐value = 0.0018). Similar findings were observed individually for PE, SGA and/or placental abruption. At 24 weeks, the aspirin‐induced prolongation of pregnancies with PD was 2.85 weeks (95% CI: 0.44–5.40), and this effect was decreased by −0.19 weeks (95% CI: −0.33 to −0.05) for each week of gestation; therefore, at 28 and 32 weeks' gestation, the aspirin‐induced prolongation was 2.09 and 1.33 weeks, respectively.Conclusions: In this secondary analysis of a cluster randomised trial, women at high risk of PE who are destined to develop a clinical spectrum of PD may benefit from longer pregnancy duration through aspirin administration in early pregnancy. Aspirin may delay the GAD due to PD, particularly benefiting those deliveries that would occur at earlier gestations without aspirin administration.
- 26 April 2021
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (3) , 597-604
Prenatal Diagnosis of Fetal Oral Masses by Ultrasound Combined With Magnetic Resonance Imaging
Objectives: To analyze the imaging manifestations of common fetal oral masses by ultrasound combined with magnetic resonance imaging (MRI) and to discuss their differential diagnoses.Methods: A retrospective study of 6 fetuses with oral masses was performed at a tertiary referral center. The imaging features of prenatal ultrasonography and MRI in the diagnosis of fetal oral masses were analyzed.Results: Histopathological examination and/or postpartum ultrasound revealed lymphangioma malformation in 2 fetuses, and mucosal retention cyst, mature teratoma, immature teratoma, and cranial meningocele in 1 fetus, respectively. The teratoma had a characteristic sonographic appearance. In our study, the 4 cases of cystic masses did not have an abnormal vessel architecture. Supplemental MRI revealed a mass effect at the level of the hypopharynx, and in 2 cases with polyhydramnios, the mass obstructed the fetuses' upper airway. Thus, ex‐utero intrapartum therapy surgery was performed to secure the newborn's airway.Conclusions: Oral fetal tumors represent rare congenital malformations. This study shows that a prenatal diagnosis of oral masses is feasible by ultrasound examination. MRI can further confirm the results of ultrasonography and clearly show the relationship between the mass and the hypopharynx. Ultrasonography combined with MRI could, to a large extent, facilitate early detection and appropriate treatment and improve outcome.
- 26 April 2021
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (3) , 597-604
Prenatal Diagnosis of Fetal Oral Masses by Ultrasound Combined With Magnetic Resonance Imaging
Objectives: To analyze the imaging manifestations of common fetal oral masses by ultrasound combined with magnetic resonance imaging (MRI) and to discuss their differential diagnoses.Methods: A retrospective study of 6 fetuses with oral masses was performed at a tertiary referral center. The imaging features of prenatal ultrasonography and MRI in the diagnosis of fetal oral masses were analyzed.Results: Histopathological examination and/or postpartum ultrasound revealed lymphangioma malformation in 2 fetuses, and mucosal retention cyst, mature teratoma, immature teratoma, and cranial meningocele in 1 fetus, respectively. The teratoma had a characteristic sonographic appearance. In our study, the 4 cases of cystic masses did not have an abnormal vessel architecture. Supplemental MRI revealed a mass effect at the level of the hypopharynx, and in 2 cases with polyhydramnios, the mass obstructed the fetuses' upper airway. Thus, ex‐utero intrapartum therapy surgery was performed to secure the newborn's airway.Conclusions: Oral fetal tumors represent rare congenital malformations. This study shows that a prenatal diagnosis of oral masses is feasible by ultrasound examination. MRI can further confirm the results of ultrasonography and clearly show the relationship between the mass and the hypopharynx. Ultrasonography combined with MRI could, to a large extent, facilitate early detection and appropriate treatment and improve outcome.